ES2134199T3 - Acido glutamico-descarboxilasa clonada. - Google Patents

Acido glutamico-descarboxilasa clonada.

Info

Publication number
ES2134199T3
ES2134199T3 ES91919674T ES91919674T ES2134199T3 ES 2134199 T3 ES2134199 T3 ES 2134199T3 ES 91919674 T ES91919674 T ES 91919674T ES 91919674 T ES91919674 T ES 91919674T ES 2134199 T3 ES2134199 T3 ES 2134199T3
Authority
ES
Spain
Prior art keywords
sub
gad
cadn
molecules
coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919674T
Other languages
English (en)
Inventor
Allan J Tobin
Mark G Erlander
Daniel L Kaufman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24346149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2134199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2134199T3 publication Critical patent/ES2134199T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)

Abstract

MOLECULAS DE CADN QUE CODIFICAN POLIPEPTIDOS DE LA GAD SUB 65. LA INVENCION PRESENTA MOLECULAS DE CADN QUE CONTIENEN UNA PARTE DE LA SECUENCIA DE CADN DE LA GAD SUB 65 QUE CODIFICAN AL MENOS UN EPITOPE PARA AUTOANTICUERPOS DE LA GAD SUB 65. LA INVENCION PRESENTA TAMBIEN ELEMENTOS DE CLONACION CAPACES DE REPLICA Y EXPRESION QUE CONTIENEN MOLECULAS DE CADN QUE CODIFICAN LA GAD SUB 65. LA INVENCION PRESENTA ADEMAS HUESPEDES TRANSFORMADOS EN UN ELEMENTO QUE TIENE UNA MOLECULA DE CADN QUE CODIFICA LA GAD SUB 65. EN OTRA PUESTA EN PRACTICA DE LA INVENCION, LA INVENCION PREVE LA DETECCION DE AUTOANTICUERPOS CONTRA LA GAD SUB 65 UTILIZANDO LOS POLIPEPTIDOS DE LA GAD SUB 65 CODIFICADOS POR LAS MOLECULAS DE CADN DE LA INVENCION.
ES91919674T 1990-09-21 1991-09-23 Acido glutamico-descarboxilasa clonada. Expired - Lifetime ES2134199T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/586,536 US6682906B1 (en) 1990-09-21 1990-09-21 Cloned glutamic acid decarboxylase

Publications (1)

Publication Number Publication Date
ES2134199T3 true ES2134199T3 (es) 1999-10-01

Family

ID=24346149

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919674T Expired - Lifetime ES2134199T3 (es) 1990-09-21 1991-09-23 Acido glutamico-descarboxilasa clonada.

Country Status (11)

Country Link
US (3) US6682906B1 (es)
EP (1) EP0502188B1 (es)
JP (3) JPH05503220A (es)
KR (1) KR100220277B1 (es)
AT (1) ATE181962T1 (es)
CA (1) CA2040555C (es)
DE (1) DE69131419T2 (es)
DK (1) DK0502188T3 (es)
ES (1) ES2134199T3 (es)
GR (1) GR3031082T3 (es)
WO (1) WO1992005446A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8721991A (en) * 1990-09-07 1992-03-30 Regents Of The University Of California, The Methods for the diagnosis and treatment of diabetes
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
EP0572478B1 (en) 1991-02-22 2005-09-07 The Walter And Eliza Hall Institute Of Medical Research Hbgad and higad polypeptides and nucleic acids and their use for the diagnosis and treatment of gad autoantigen associated diseases
AU1749692A (en) * 1991-05-03 1992-12-21 Novo Nordisk A/S Islet cell autoantigen (gad) for the detection of preclinical diabetes
CA2103159A1 (en) * 1991-05-15 1992-11-16 Ake Lernmark Cloning and expression of human islet glutamic acid decarboxylase autoantigen
DE4237244A1 (de) * 1992-11-04 1994-05-05 Elias Entwicklungslabor Fuer I Verfahren zur Herstellung hochreiner humaner GAD-1- und GAD-2- Proteine
JP4242446B2 (ja) * 1992-12-03 2009-03-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 糖尿病及びスティフマン症候群の診断及び治療用改良試薬及び方法
ZA94845B (en) * 1993-02-09 1994-11-11 Univ Monash Methods for the diagnosis of diabetes and prediabetic conditions
GB9319429D0 (en) 1993-09-21 1993-11-03 London Health Ass Methods and products for controlling immune responses in mammals
CA2140591A1 (en) 1994-01-20 1995-07-21 Josef Endl Antigen-specific, activated t lymphocytes, detection and use
FR2726575B1 (fr) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa Virus recombinants, preparation et utilisation en therapie genique
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
FR2717823B1 (fr) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
SE9401118L (sv) * 1994-03-31 1995-10-01 Synectics Medical Ab GAD, en metod för framställning av modifierat GAD samt en metod för att tillföra modifierat GAD samt peptid
DE4418223A1 (de) 1994-05-25 1995-11-30 Boehringer Mannheim Gmbh Verfahren zum Nachweis des Vorliegens eines Insulin-abhängigen Diabetes mellitus
US5561049A (en) * 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
CA2213301C (en) * 1995-02-20 2010-01-26 Amrad Operations Pty. Ltd. Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
SE9503379D0 (sv) * 1995-09-29 1995-09-29 Synectics Medical Ab A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
WO1997017451A2 (en) * 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US6093396A (en) * 1996-09-27 2000-07-25 Diamyd Therapeutics Ab Modified glutamic acid decarboxylase (GAD)
CA2281949A1 (en) 1997-02-25 1998-08-27 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
EP1793000A1 (en) * 1997-02-25 2007-06-06 GTC Biotherapeutics, Inc. Transgenically produced non-secreted proteins
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
EP1102067A4 (en) * 1999-06-01 2001-10-17 Kyokuto Pharmaceutical Ind Co ANTI-GAD ANTIBODY ASSAY METHOD AND KIT
DE60106763T2 (de) * 2000-05-23 2006-01-26 Neurologix, Inc. Glutaminsäure decarboxylase (gad) abgabesystem zur behandlung neurodegeneraliver erkrankungen
US7695959B2 (en) * 2000-05-23 2010-04-13 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
AU2003300681A1 (en) * 2002-10-02 2004-05-04 Diamyd Medical Ab Formulation of glutarmic acid decarboxylase (gad65) and serum albumin
WO2006098485A1 (ja) * 2005-03-15 2006-09-21 Tokyo University Of Science グルタミン酸脱炭酸酵素変異体
PL2137315T3 (pl) 2007-03-16 2015-02-27 Genomatica Inc Kompozycje i sposoby do biosyntezy 1,4-butanodiolu i jego prekursorów
EP2146741A4 (en) * 2007-04-24 2010-08-04 Diamyd Therapeutics Ab DRUGS AND METHODS FOR TREATING AUTOIMMUNE DISEASE AND CANCER
US7947483B2 (en) 2007-08-10 2011-05-24 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
EP2334800B1 (en) 2008-09-10 2018-12-26 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol
VN29235A1 (es) * 2009-06-04 2012-03-26
MY187676A (en) 2009-06-04 2021-10-08 Genomatica Inc Microorganisms for the production of 1,4-butanediol and related methods
CN102762735B (zh) * 2009-10-13 2016-08-03 基因组股份公司 生产1,4-丁二醇、4-羟基丁醛、4-羟基丁酰-coa、腐胺和相关化合物的微生物及其相关方法
US8530210B2 (en) 2009-11-25 2013-09-10 Genomatica, Inc. Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone
US8637286B2 (en) * 2010-02-23 2014-01-28 Genomatica, Inc. Methods for increasing product yields
US8048661B2 (en) * 2010-02-23 2011-11-01 Genomatica, Inc. Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
EP3831951A3 (en) 2012-06-04 2021-09-15 Genomatica, Inc. Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487830A (en) 1982-05-14 1984-12-11 American Hoechst Corporation Enzyme/immunofluorescent assay for autoantibodies
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
AU4815890A (en) 1988-12-13 1990-07-10 University Of Florida Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
NO306996B1 (no) 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
CA2089742C (en) * 1990-08-17 2002-05-14 Mark A. Atkinson Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus
AU8721991A (en) * 1990-09-07 1992-03-30 Regents Of The University Of California, The Methods for the diagnosis and treatment of diabetes
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5475086A (en) * 1990-09-21 1995-12-12 The Regents Of The University Of California Cloned glutamic acid decarboxylase peptides
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
EP0572478B1 (en) * 1991-02-22 2005-09-07 The Walter And Eliza Hall Institute Of Medical Research Hbgad and higad polypeptides and nucleic acids and their use for the diagnosis and treatment of gad autoantigen associated diseases
CA2103159A1 (en) * 1991-05-15 1992-11-16 Ake Lernmark Cloning and expression of human islet glutamic acid decarboxylase autoantigen

Also Published As

Publication number Publication date
US6682906B1 (en) 2004-01-27
EP0502188B1 (en) 1999-07-07
GR3031082T3 (en) 1999-12-31
JP2007236390A (ja) 2007-09-20
EP0502188A4 (en) 1994-05-18
DK0502188T3 (da) 2000-01-24
CA2040555C (en) 2003-11-04
DE69131419D1 (de) 1999-08-12
ATE181962T1 (de) 1999-07-15
DE69131419T2 (de) 2000-03-30
AU8877191A (en) 1992-04-15
US6277586B1 (en) 2001-08-21
KR920702233A (ko) 1992-09-03
US20050164342A1 (en) 2005-07-28
US7329511B2 (en) 2008-02-12
AU657501B2 (en) 1995-03-16
WO1992005446A1 (en) 1992-04-02
KR100220277B1 (ko) 1999-09-15
CA2040555A1 (en) 1992-03-22
JPH05503220A (ja) 1993-06-03
EP0502188A1 (en) 1992-09-09
JP2000333671A (ja) 2000-12-05

Similar Documents

Publication Publication Date Title
ES2134199T3 (es) Acido glutamico-descarboxilasa clonada.
ES2158386T3 (es) Soporte fijador para un recipiente de bebidas.
NO913524D0 (no) Nukleotidsekvens som koder for et ytre membranprotein franeisseria meningitidis, samt anvendelse derav.
DE69014440D1 (de) Sprachcodierungs-/-decodierungssystem.
BR9610262B1 (pt) Compostos e métodos para a imunoterapia e diagnose de tuberculose.
ES2141459T3 (es) Medios para la correcta fijacion de un cartucho de varios componentes a un distribuidor.
ES538613A0 (es) Perfeccionamientos introducidos en cristales para aplicaciones oftalmicas.
DK434884A (da) Benzothiopen-derivater til anvendelse som midler mod astma samt farmaceutiske formuleringer indeholdende saadanne derivater
ES2174768T1 (es) Genes de corynebacterium glutamicum que codifican proteinas del sistema fosfoenolpiruvato: azucar fosfotransferasa.
FR2193292A1 (es)
ES2100360T3 (es) Nuevos derivados de gangliosidos.
MX9206586A (es) Proceso para la preparacion de daunorubicina.
ES2005757A6 (es) Un metodo para producir proteinas de fusion por medios recombinantes.
DK0691404T3 (da) Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf
ES8503373A1 (es) Un procedimiento de preparacion de un vector de transferencia de adn.
FI893456A7 (fi) Text-tv-dekoder.
IT212946Z2 (it) Un tappo otturatore in fuznione di sigillo per applicazioni su fusti di birra e per altri impieghi, realizzato in resina sintetica.
ES517724A0 (es) Perfeccionamientos en los dispositivos valvula-regulador de presion para botellas de gas licuado.
ES1005553Y (es) Retrovisor para gafas.
MX171988B (es) Un cifrador mejorado con autocalibracion
ES1008227Y (es) Tapon-obturador para frascos monopieza.
ES1026383Y (es) Capuchon publicitario para botellas.
ES1019426Y (es) Tapon-grifo utilizable en envases para liquidos.
ES1013425Y (es) Agrupador para envases tipo botella.
NO920500D0 (no) Nukleotidsekvens som koder for et ytre membranprotein franeisseria meningitidis, samt anvendelse derav

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 502188

Country of ref document: ES